Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous mRNA-encoding NSCLC neoantigens dendritic cell vaccine

A dendritic cell (DC)–based cancer vaccine in which the autologous, in vitro activated DCs are loaded with messenger RNA (mRNA) encoding neoantigens from the patient’s non-small cell lung cancer (NSCLC), with potential immunomodulating and antineoplastic activities. Upon administration of autologous mRNA–encoding NSCLC neoantigens DC vaccine, the mRNA gets expressed into neoantigens in cells and the neoantgens activate the immune system to induce robust neoantigen-specific T-cell responses against the NSCLCs expressing these neoantigens. The neoantigens are predicted from the patient-individual tumor's mutanome.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MIDRIXNEO-LUNG dendritic cell vaccine
autologous mRNA–loaded NSCLC DC vaccine
MIDRIXNEO-LUNG autologous DC vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search